THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Monday, March 02, 2026 | Issue #001

Data quality notice — read this first: Today's pull returned no fresh data across all 12 tracked categories. Every specific number in this issue is background context or prior-sourced data, not today's market signal. The Polymarket odds are live as of this morning. Everything else — compounder pricing, vendor ratings, COA discrepancy rates, API costs — is sourced from prior community data and flagged as such throughout. Issue #2 will have a live baseline to compare against. You deserve to know that upfront, not buried in a footer.

This is Issue #1. No prior data means no delta flags, no price-move comparisons, no scored predictions yet. Starting Tuesday, March 3, every forward-looking statement gets scored publicly when the data comes in. That's the deal.

COMPOUND WATCH

Prices below are community-sourced estimates as of late February 2026 — no fresh compounder pricing was available in today's data pull. Treat as directional, not current.

BPC-157 | Evidence: [Phase 2 — first human RCT now recruiting] | Gray-market: ~$25-60/vial (5mg, research vendor) | Compounder: ~$150-300/month Tirzepatide (compounded) | Evidence: [Phase 3 — approved, brand Zepbound] | Compounder: ~$200-400/month | Brand (Zepbound): ~$1,000+/month Retatrutide | Evidence: [Phase 3 — recruiting] | Availability: gray-market only [Unverified], no legal compounding pathway Survodutide | Evidence: [Phase 3 — active] | Availability: gray-market only [Unverified] Semaglutide (compounded) | Evidence: [Phase 3 — approved, brand Ozempic/Wegovy] | Compounder: ~$150-350/month | Brand: ~$900-1,100/month CJC-1295 / Ipamorelin | Evidence: [Animal / Anecdotal] | Status: Category 2, enforcement discretion only TB-500 | Evidence: [Animal] | Status: Category 2, same limbo GHK-Cu | Evidence: [In Vitro / Animal] | Status: Category 2, same limbo

The number that anchors your week: Only 72 registered 503B outsourcing facilities remain in the U.S. That is the entire legal compounding supply chain for injectable peptides and GLP-1s. When one exits — voluntarily or via warning letter — the bottleneck tightens and prices at surviving facilities move. Watch that number like a cattle trader watches kill pace.

The markup that explains everything: The spread on compounded semaglutide runs roughly 100x from Chinese API (~$5-10/gram equivalent, prior-sourced estimate) to brand Ozempic (~$900/month). Your compounder at $200-350/month is capturing real value. That spread is also why the gray market exists and why it survives every regulatory cycle.

VENDOR SIGNAL

No fresh Finnrick rating changes, no new Janoshik HPLC results, and no FDA warning letters surfaced in today's data pull. This is a baseline entry. Any movement from here is meaningful.

What the structural baseline looks like:

[Verified] — Finnrick-listed vendors with recent independent HPLC confirmation at 98%+ purity. Check finnrick.com directly before your next order. Their live rankings are the closest thing to a real-time purity database this market has. Do not rely on a vendor's own COA alone.

[COA Only] — The default for most vendors you'll find on r/peptides. A vendor-supplied COA is better than nothing. But community-compiled independent testing data (estimate, not a formally published study — treat as directional) suggests roughly 15-20% of vendor COAs show discrepancies when independently verified. That's approximately 1-in-6 vials you're injecting based on paperwork that hasn't been checked. If you have a source that pins this number more precisely, reply and tell me — I'll update it in Issue #2.

[Flagged] — No new flags today. If a vendor you use received an FDA warning letter in the past 18 months, treat their current product as [COA Only] at best until independently re-verified.

For 503A vs. 503B: 503B facilities operate under FDA oversight with mandatory sterility and potency testing. 503A compounds require a valid patient-specific prescription and cannot be made in bulk — meaning no pre-made inventory, slower supply, and more variability when demand spikes. Not structurally worse on quality, but meaningfully less predictable on availability. That's the decision-relevant difference.

Action: If your vendor isn't in the Finnrick database, that's information — it means no one has paid to independently verify them yet. Decide accordingly.

TRIAL TRACKER

Track any trial below by searching its NCT number at clinicaltrials.gov.

🔬 BPC-157 — Phase 2 Human RCT [NCT07437547] Status: Recruiting | Started: February 2, 2026 Indication: Acute hamstring muscle strain and skeletal muscle injury.

This is the first Phase 2 human trial for BPC-157 ever registered on ClinicalTrials.gov. The indication is narrow — hamstring strain, not the broad gut-healing or systemic repair use case that drives most gray-market demand. But the mechanism being tested (accelerated skeletal muscle repair) overlaps with the injury recovery use cases that make up a significant share of why people are injecting this compound. The trial has zero results yet — it only began recruiting four weeks ago. What exists is recruiting status, not data. If this trial produces positive Phase 2 results, it creates a clinical pathway. If it fails, it's the first hard human evidence against the animal-study narrative. Either outcome matters more than any anecdote. No estimated completion date published yet. Watch for enrollment updates monthly.

🔬 Retatrutide — Phase 3 [NCT07357415] Status: Recruiting | Started: January 24, 2026 Indication: Obesity/overweight without Type 2 diabetes.

Retatrutide (GIP/GLP-1/glucagon triple agonist) showed ~24% body weight reduction in Phase 2 — above tirzepatide's ~22% and semaglutide's ~15% (Phase 2 data, prior-sourced). This Phase 3 trial is the pivotal study for approval. Lilly is running a full development program: a maintenance-of-weight-reduction study (NCT06859268, active not recruiting since March 2025) and an insulin sensitivity study (Phase 1, NCT06982859, recruiting since June 2025). Gray-market retatrutide exists today [Unverified — no independent supply chain confirmation]. If you're using it, you're running a personal n=1 experiment ahead of the clinical data. Dose conservatively and know that.

🔬 Survodutide — Phase 3 MASH [NCT06632444 & NCT06632457] Status: Recruiting | Started: September 2024 and November 2024 respectively Indication: MASH with moderate-to-advanced liver fibrosis and cirrhosis.

We're introducing this as a baseline entry — these trials have been running since 2024 but have no published interim data. We'll track monthly for enrollment updates and any data releases. The reason it's here: survodutide (GLP-1/glucagon dual agonist) is being tested specifically for liver disease, and the liver-protection angle will drive biohacking demand if Phase 3 data is positive. No legal compounding pathway exists. File under: watch the trial, don't buy the gray-market version until Phase 3 reads out.

THE ODDS

Prediction market signals translated for the person reconstituting a vial right now. Probabilities as of March 2, 2026.

Lead signal this week: China/Taiwan tail risk — 10% probability ($10,861,621 traded)

The volume is the signal. Nearly $11M has traded on whether China invades Taiwan by end of 2026 — by far the most-traded question in today's data. At 10%, this is a tail risk, not a base case. But the volume tells you sophisticated money is actively pricing it. For gray-market peptide users: QSC, SRY, GYC, and the broader Chinese API supply chain would face immediate customs seizure risk, shipping disruption, and potential sanctions in a Taiwan conflict scenario. Your entire gray-market sourcing infrastructure runs through that supply chain. Decision: A 3-month buffer of stable lyophilized peptides from a verified vendor is reasonable tail-risk management at 10% odds — not panic buying, just position sizing against a low-probability, high-impact event.

🔴 Inflation above 3% in 2026: 80% probability ($114,756 traded) This is the most directly relevant signal for your monthly peptide budget. Compounding pharmacy overhead — labor, supplies, facility costs — tracks closer to 1.5-2x CPI than to headline inflation (rule of thumb, not a sourced multiplier — if you have better data, reply). Chinese API costs are partially insulated by dollar strength, but not fully. Rough implication: your $300/month protocol likely costs $315-330/month by Q4 2026. If you're considering stocking up on stable lyophilized peptides from a verified vendor, the inflation math slightly favors doing it now rather than Q3.

🟡 US Recession by end of 2026: 32% probability ($515,394 traded) Below 40%, historical patterns suggest discretionary health spending holds and compounder order volumes stay stable. Above 40%, the gray-market sourcing share grows as people exit $300-500/month compounder relationships and move to $50-100/month research vendor equivalents. At 32%, we're not there yet. Decision threshold: If recession odds drift above 40% on sustained volume (>$1M additional traded — use this as a rough filter for signal vs. noise), verify your backup gray-market vendor is still operational and independently tested. That's the moment to have a fallback, not after the shift happens.

🟡 No Fed rate cuts in 2026: 23% probability ($1,839,246 traded) The 77% probability of at least one cut is a mild headwind for gray-market pricing — rate cuts weaken the dollar modestly, which raises the effective cost of Chinese API imports. Not a crisis-level input. Decision: Minor. Don't make sourcing decisions based on this alone.

The signal the rest of the peptide world is ignoring: 80% inflation odds + 10% Taiwan tail risk + 72 remaining 503B facilities = a supply chain that is structurally more fragile than the price you're paying suggests. Diversify your sourcing before you need to.

SIGNAL VS. NOISE

SIGNAL: BPC-157 Phase 2 trial now recruiting (NCT07437547) This is structural — it changes the evidence grade from [Animal] to [Phase 2 recruiting] for the first time in this compound's history. The signal isn't "BPC-157 works." The signal is "BPC-157 is now being tested in humans, and the result will matter in both directions." If you're currently using BPC-157 [Animal / Anecdotal], this trial doesn't validate your protocol. But it's the first step toward a world where it might — and the first step toward hard evidence against it if it fails.

SIGNAL: Retatrutide Phase 3 recruiting with obesity-only indication Lilly is running a serious multi-study development program. The Phase 2 ~24% weight reduction data was not a fluke. The gray-market version you can buy today [Unverified] is not the same compound being studied in these trials in any verified sense. Know that before you dose.

NOISE: Any claim that RFK Jr.'s peptide reclassification is "done" RFK announced intent to reclassify ~14 of 19 Category 2 peptides back to Category 1. No formal FDA rule has been issued as of March 2, 2026. What exists is enforcement discretion — FDA is choosing not to prioritize action, which is not the same as those compounds being legal to compound. BPC-157, TB-500, CJC-1295, Ipamorelin, and GHK-Cu are still Category 2. Compounders producing them have no legal shield if enforcement priorities shift. Anyone telling you these are "cleared" is misreading the situation.

NOISE: Vendor COAs as safety validation A vendor's own certificate of analysis is a piece of paper. Community testing data suggests roughly 1-in-6 COA-backed products fails when independently verified (estimate — see Vendor Signal for sourcing caveat). The noise is the assumption that COA = verified. The signal is an independent HPLC result from Janoshik or a Finnrick-listed vendor.

REGULATORY RADAR

The single most important regulatory fact as of March 2, 2026: No formal FDA rulemaking has been issued on peptide reclassification. RFK Jr.'s stated intent to move ~14 Category 2 peptides back to Category 1 is policy direction, not law. The compounds your compounder may be producing — BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu — remain legally in Category 2. Compounders producing them are relying on enforcement discretion, which can be withdrawn without notice and without a rulemaking process. Watch for: a formal proposed rule in the Federal Register. That's the trigger that converts enforcement discretion into actual legal protection. Until it's published there, treat Category 2 status as unchanged.

The Hims-Novo Nordisk deal (March 2026): A deal between Hims & Hers and Novo Nordisk was announced in early March 2026. No specific terms — pricing commitments, distribution structure, or compounding exit requirements — are available in today's data. We will not speculate about structural implications of a deal whose terms we don't have. The question that matters: Does Hims retain a compounded semaglutide option, or does this deal require them to exit compounding entirely? Watch for SEC filings or press releases with specific pricing terms. We'll cover it in Issue #2 when the terms surface.

No FDA warning letters or enforcement actions surfaced today. Baseline entry. Issue #2 flags any changes.

WHAT TO WATCH

This week — specific triggers, not vague monitoring:

• NCT07437547 (BPC-157 Phase 2): Check clinicaltrials.gov for enrollment updates. If a recruiting site posts near you, r/peptides will surface it within 24 hours. Action: set a ClinicalTrials.gov alert for this NCT number now.
• Hims-Novo deal terms: Watch for SEC filings (search EDGAR for "Hims & Hers" filings after March 2) or press releases with specific pricing and distribution structure. The compounding-exit question is the one that affects your sourcing options directly.
• Finnrick.com: No rating changes in today's data. Check the live rankings before your next order. Any movement from this baseline is meaningful.

This month:

• RFK/FDA reclassification: No Federal Register notice filed as of today. Action: search federalregister.gov for "503B" or "bulk drug substances" monthly. A formal proposed rule is the only event that changes the legal status of Category 2 peptides.
• Recession odds on Polymarket: Current 32%. If this drifts above 40% on sustained volume (>$1M additional traded), reassess your compounder vs. gray-market allocation. That's the threshold where historical patterns suggest discretionary health spending shifts — and where your backup vendor needs to be verified and ready, not identified for the first time.
• Retatrutide Phase 3 enrollment pace (NCT07357415): Started January 24. Fast enrollment signals Lilly confidence and an aggressive approval timeline. Slow enrollment signals protocol or patient selection issues. Check ClinicalTrials.gov enrollment status monthly.

The forward-looking line to remember: The BPC-157 Phase 2 trial is the most important thing to happen to this compound's credibility in a decade — and the result could go either way. If it fails, the [Animal] evidence base takes a hit that no amount of anecdote recovers. If it succeeds, the entire Category 2 reclassification argument gets stronger. This is the single most important data point to track in 2026 for the gray-market peptide community.

Data gaps today: No fresh Finnrick ratings, no new Janoshik results, no FDA warning letters, no compounder pricing updates, no Reddit trending data, no Hims-Novo deal terms. I won't construct a story around missing numbers. Check finnrick.com for live vendor rankings. Check r/peptides for community sourcing reports. Issue #2 has a baseline to compare against.

Reply to this email with feedback — what compounds, what vendors, what regulatory questions matter most to you. Issue #2 is better if you tell me what you need.

Stay curious, stay skeptical. — The Dose